(Q27851801)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22608338%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

title

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22608338%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

main subject

brain

0 references

phase I clinical trial

0 references

0 references

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22608338%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Michael P. Brown

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22608338%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Richard F. Kefford

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22608338%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

3

Razelle Kurzrock

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22608338%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

9

Michael Millward

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22608338%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

14

Peter Lebowitz

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22608338%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

7

Omid Hamid

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22608338%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

1

Gerald S Falchook

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22608338%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

16

Daniele Ouellet

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22608338%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

8

Jeffrey R Infante

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22608338%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

10

Anna C Pavlick

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22608338%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

author name string

Kevin B Kim

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22608338%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Tobias H Arkenau

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22608338%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Steven J O'Day

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22608338%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Samuel C Blackman

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22608338%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

C Martin Curtis

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22608338%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Bo Ma

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22608338%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

language of work or name

English

0 references

publication date

1 May 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22608338%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22608338%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

volume

379

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22608338%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

page(s)

1893-1901

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22608338%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

issue

9829

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22608338%20AND%20SRC:MED&resulttype=core&format=json

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

1 February 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4109288

Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4109288

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4109288

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4109288

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4109288

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4109288

Mutations of the BRAF gene in human cancer

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4109288

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4109288

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4109288

BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4109288

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4109288

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4109288

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4109288

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4109288

Final version of 2009 AJCC melanoma staging and classification

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4109288

RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4109288

Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4109288

Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4109288

B-RAF is a therapeutic target in melanoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4109288

Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4109288

A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4109288

Cranial irradiation after surgical excision of brain metastases in melanoma patients.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4109288

Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4109288

Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4109288

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

27 November 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960398-5

7 January 2021

Prognostic factors for survival in melanoma patients with brain metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960398-5

7 January 2021

Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960398-5

7 January 2021

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960398-5

7 January 2021

Accelerated titration designs for phase I clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960398-5

7 January 2021

Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960398-5

7 January 2021

10.1016/S0140-6736(12)60398-5

Identifiers

DOI

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22608338%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

1 reference

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22608338%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

2 references